Williams Jones Wealth Management LLC. purchased a new stake in shares of Enovis Co. (NYSE:ENOV – Get Rating) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 130,766 shares of the company’s stock, valued at approximately $5,203,000. Williams Jones Wealth Management LLC. owned about 0.24% of Enovis at the end of the most recent reporting period.
Separately, Argent Capital Management LLC acquired a new position in shares of Enovis in the first quarter valued at approximately $470,000. 89.40% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
ENOV has been the subject of a number of research reports. Argus initiated coverage on shares of Enovis in a report on Tuesday, June 28th. They issued a “hold” rating for the company. Wells Fargo & Company decreased their price target on shares of Enovis to $60.00 in a research note on Friday, July 22nd. Finally, Loop Capital reiterated a “buy” rating and issued a $68.00 price target on shares of Enovis in a research note on Monday, June 27th.
Insider Transactions at Enovis
Enovis Stock Up 2.0 %
Shares of Enovis stock opened at $51.55 on Friday. Enovis Co. has a 52-week low of $47.73 and a 52-week high of $164.01. The business has a 50 day moving average price of $55.38. The stock has a market capitalization of $2.79 billion, a P/E ratio of 23.54, a P/E/G ratio of 1.05 and a beta of 2.14.
Enovis (NYSE:ENOV – Get Rating) last issued its quarterly earnings data on Thursday, August 4th. The company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.10. The business had revenue of $395.12 million during the quarter, compared to the consensus estimate of $400.23 million. Enovis had a net margin of 3.49% and a return on equity of 5.39%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.68 EPS. As a group, analysts predict that Enovis Co. will post 2.27 EPS for the current year.
Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.
- Get a free copy of the StockNews.com research report on Enovis (ENOV)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.